Bozitinib 是一种可透过血脑屏障的、高效的、选择性的的、 ATP 竞争性的小分子c-MET激酶抑制剂，能够与酪氨酸激酶超家族的常规 ATP 结合口袋结合。

Bozitinib (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily.

Bozitinib (30 μM; 6 hours) inhibits the phosphorylation of MET and STAT3. Bozitinib has a robust inhibitory effect on MET and its downstream signaling pathways.

1440964-89-5

C20H15F3N8

424.38

PLB-1001;CBT-101

DMSO:47 mg/mL (110.74 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years